Skip to main content

Peer Review reports

From: Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review

Original Submission
27 Oct 2021 Submitted Original manuscript
25 Nov 2021 Reviewed Reviewer Report
29 Nov 2021 Reviewed Reviewer Report
14 Dec 2021 Author responded Author comments - Libo Wang
23 Dec 2021 Reviewed Reviewer Report
4 Jan 2022 Reviewed Reviewer Report
Resubmission - Version 2
14 Dec 2021 Submitted Manuscript version 2
Publishing
5 Jan 2022 Editorially accepted
4 Apr 2022 Article published 10.1186/s12887-022-03229-x

You can find further information about peer review here.

Back to article page